Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of KOA SHOJI HOLDINGS CO.,LTD.. A complete text table follows the diagram.
Active pharmaceutical ingredients are the growth engine, while finished-drug marketing faces tablet competition and a costly manufacturing buildout.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Drug Substance Sales Business | 1 | 7.8B | 61.8% of reported total |
| Pharmaceutical Marketing Business | 1 | 4.8B | 38.2% of reported total |
| Other & rounding | 1 | 0 | 0.0% of reported total |
| Revenues From External Customers | 2 | 12.7B | Reported six-month total · ¥12.7B |
| Operating profit | 3 | 3.2B | 25.0% operating margin |
| Operating costs & expenses | 3 | 9.5B | Arithmetic residual to reported operating profit |
| Profit before tax | 4 | 3.1B | Reported pretax result |
| Generic-drug demand funds the move from API trading to specialized manufacturing | 4 | 54M | API volumes and newer products grow, while tablet competition, factory investment and receivables determine how much profit becomes cash. |
| Net profit attributable to owners | 5 | 2.1B | Reported parent-company result |
| Tax, attribution & other | 5 | 1.0B | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Drug Substance Sales Business | Revenues From External Customers | 7.8B |
| Pharmaceutical Marketing Business | Revenues From External Customers | 4.8B |
| Other & rounding | Revenues From External Customers | 0 |
| Revenues From External Customers | Operating profit | 3.2B |
| Revenues From External Customers | Operating costs & expenses | 9.5B |
| Operating profit | Profit before tax | 3.1B |
| Operating profit | Generic-drug demand funds the move from API trading to specialized manufacturing | 54M |
| Profit before tax | Net profit attributable to owners | 2.1B |
| Profit before tax | Tax, attribution & other | 1.0B |